Janice M Hamilton, who serves as Chief Financial Officer for RYAN SPECIALTY HOLDINGS, INC., executed a notable acquisition of company shares on June 3, 2026. Ms. Hamilton purchased a total of 6,300 shares of the company's Class A Common Stock, accumulating an aggregate value of $200,292. The purchase was spread across a range of prices, specifically between $31.17 and $32.13 per share.
The timing of this transaction is particularly noteworthy when considering the current market valuation of RYAN. As reported, the stock recently traded at $30.86, placing it in proximity to its 52-week low of $29.28. This represents a significant decline over the past year, marked by an approximate 55% decrease.
Following this recent buying activity, Ms. Hamilton's direct holdings of RYAN SPECIALTY HOLDINGS, INC. Class A Common Stock increased to 14,574 shares. Furthermore, external analysis from InvestingPro suggests that the stock may be undervalued at its current pricing levels, and additional subscription services offer nine ProTips for further evaluation.
The company's corporate financial activity also provides context for this insider movement. Ryan Specialty Group recently announced plans to increase its share repurchase program by $300 million, following the depletion of previous authorizations. This action establishes a remaining available amount of $300 million under the scope of the current buyback program.
Analyst sentiment surrounding RYAN has been mixed, presenting both positive endorsements and cautionary notes. Keefe, Bruyette & Woods maintained an Outperform rating on Ryan Specialty, elevating its price target from $42 to $44. The firm also adjusted its earnings per share projections for both 2026 and 2027, basing these adjustments on the assumption of significant future share buybacks.
In contrast, Wells Fargo issued a downgrade, moving Ryan Specialty from Overweight to Equal Weight while simultaneously lowering its price target to $31 from an initial $42. This reduction in rating reflects expectations of weaker organic growth, with the company now targeting high-single-digit growth for the current year and 0% growth specifically for the second quarter.
Adding to the varied commentary, Mizuho also adjusted its price target downward, setting it at $35 from $42. The firm maintained a Neutral rating on Ryan Specialty due to RYAN’s revised guidance for fiscal year 2026, which anticipates mid-single-digit organic growth.
Despite the varying assessments, Keefe, Bruyette & Woods reiterated its Outperform rating with a price target of $42. The firm emphasized a positive growth outlook, noting that this assessment followed investor meetings held with company executives.
Risks
- Weaker organic growth is cited by Wells Fargo as a reason for the downgrade, particularly pointing to 0% expected growth in Q2.
- The varying analyst price targets and ratings reflect differing views on the company's future performance trajectory.
More from Insider Trading